• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

地高辛还原代谢产物的尿排泄

Urinary excretion of reduced metabolites of digoxin.

作者信息

Lindenbaum J, Tse-Eng D, Butler V P, Rund D G

出版信息

Am J Med. 1981 Jul;71(1):67-74. doi: 10.1016/0002-9343(81)90260-6.

DOI:10.1016/0002-9343(81)90260-6
PMID:7246583
Abstract

The urinary excretion of the relatively cardioinactive reduced metabolites of digoxin, dihydrodigoxin and related compounds was measured by radioimmunoassay in 131 normal subjects during studies of the bioavailability of digoxin preparations. Digoxin reduction products (DRP) constitute more than 5 percent of the excretion of digoxin and its metabolites in one-third of the volunteers after the administration of single or multiple doses of digoxin. There was little or no output of DRP during the first 8 hours after a single dose, with maximal excretion usually occurring on the second day. Most subjects who excreted more than 5 percent DRP on one occasion did so with each subsequent exposure to digoxin. Six volunteers, however, in whom substantial amounts of DRP had previously been found, failed to excrete detectable quantities after subsequent doses. In two, this change occurred shortly after they took erythromycin. Urinary DRP were less after the intravenous administration compared to the oral administration of digoxin. After oral doses, DRP excretion tended to vary inversely with the bioavailability of the preparation. The findings are consistent with the hypothesis that DRP are formed as the result of the activity of a variable component of the intestinal flora. Prospective studies will be necessary to prove this hypothesis.

摘要

在一项地高辛制剂生物利用度研究中,采用放射免疫分析法对131名正常受试者地高辛、二氢地高辛及相关化合物相对心脏活性较低的还原代谢产物的尿排泄情况进行了测定。在单次或多次服用地高辛后,三分之一的志愿者体内,地高辛还原产物(DRP)占地高辛及其代谢产物排泄量的5%以上。单次给药后的前8小时,DRP排出量很少或没有,最大排泄量通常出现在第二天。大多数一次排泄DRP超过5%的受试者,在随后每次服用地高辛时均如此。然而,此前发现有大量DRP的6名志愿者,在后续给药后未能排出可检测量的DRP。其中两名志愿者在服用红霉素后不久就出现了这种变化。与口服地高辛相比,静脉注射后尿中DRP较少。口服给药后,DRP排泄量往往与制剂的生物利用度呈负相关。这些发现与以下假设一致,即DRP是肠道菌群可变成分活性的结果。需要进行前瞻性研究来证实这一假设。

相似文献

1
Urinary excretion of reduced metabolites of digoxin.地高辛还原代谢产物的尿排泄
Am J Med. 1981 Jul;71(1):67-74. doi: 10.1016/0002-9343(81)90260-6.
2
Decreased digoxin cardioinactive-reduced metabolites after administration as an encapsulated liquid concentrate.
Clin Pharmacol Ther. 1983 Dec;34(6):738-43. doi: 10.1038/clpt.1983.243.
3
Variability of steady-state digoxin kinetics during administration of tablets or capsules.
Clin Pharmacol Ther. 1986 Mar;39(3):306-12. doi: 10.1038/clpt.1986.44.
4
Lack of difference in digoxin urinary excretion with two intravenous infusion rates.
Clin Pharmacol Ther. 1981 Sep;30(3):317-20. doi: 10.1038/clpt.1981.166.
5
Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.肠道菌群对洋地黄毒苷的灭活作用:抗生素治疗可使其逆转。
N Engl J Med. 1981 Oct 1;305(14):789-94. doi: 10.1056/NEJM198110013051403.
6
The development and application of a radioimmunoassay for dihydrodigoxin, a digoxin metabolite.地高辛代谢产物二氢地高辛放射免疫测定法的开发与应用。
J Pharmacol Exp Ther. 1982 Apr;221(1):123-31.
7
Inactivation of digoxin by Eubacterium lentum, an anaerobe of the human gut flora.
Trans Assoc Am Physicians. 1982;95:22-9.
8
Excretion of digoxin and its metabolites in urine after a single oral dose in healthy subjects.健康受试者单次口服剂量后地高辛及其代谢产物在尿液中的排泄情况。
Biopharm Drug Dispos. 1982 Jul-Sep;3(3):211-8. doi: 10.1002/bdd.2510030304.
9
The measurement of urinary digoxin and dihydrodigoxin by radioimmunoassay and by mass spectroscopy.采用放射免疫分析法和质谱分析法测定尿中地高辛和二氢地高辛。
Clin Chim Acta. 1975 Jul 23;62(2):213-24. doi: 10.1016/0009-8981(75)90230-2.
10
Absorption of beta-methyl-digoxin determined after a single dose and under steady state conditions.单次给药后及稳态条件下测定的β-甲基地高辛的吸收情况。
Eur J Clin Pharmacol. 1976 Feb 6;9(4):307-14. doi: 10.1007/BF00561665.

引用本文的文献

1
Gut microbe-derived lactic acid optimizes host energy metabolism during starvation.肠道微生物衍生的乳酸在饥饿期间优化宿主能量代谢。
bioRxiv. 2025 May 28:2025.05.27.656452. doi: 10.1101/2025.05.27.656452.
2
Tutorial: Microbiome studies in drug metabolism.教程:药物代谢中的微生物组研究。
Clin Transl Sci. 2022 Dec;15(12):2812-2837. doi: 10.1111/cts.13416. Epub 2022 Sep 30.
3
Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability.肠道微生物组对药物处置、药代动力学和药效动力学变异性的贡献。
Clin Pharmacokinet. 2021 Aug;60(8):971-984. doi: 10.1007/s40262-021-01032-y. Epub 2021 May 7.
4
Personalized Mapping of Drug Metabolism by the Human Gut Microbiome.人肠道微生物组对药物代谢的个性化映射。
Cell. 2020 Jun 25;181(7):1661-1679.e22. doi: 10.1016/j.cell.2020.05.001. Epub 2020 Jun 10.
5
Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins.发现并鉴定了一种在人类肠道中普遍存在的细菌酶,该酶足以使一类植物毒素失活。
Elife. 2018 May 15;7:e33953. doi: 10.7554/eLife.33953.
6
Impact of antiretroviral drugs on the microbiome: unknown answers to important questions.抗逆转录病毒药物对微生物组的影响:重要问题的未知答案。
Curr Opin HIV AIDS. 2018 Jan;13(1):53-60. doi: 10.1097/COH.0000000000000428.
7
Gut microbiota modulation of chemotherapy efficacy and toxicity.肠道微生物群调节化疗疗效和毒性。
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365. doi: 10.1038/nrgastro.2017.20. Epub 2017 Mar 8.
8
Gut microbiome interactions with drug metabolism, efficacy, and toxicity.肠道微生物群与药物代谢、疗效及毒性的相互作用。
Transl Res. 2017 Jan;179:204-222. doi: 10.1016/j.trsl.2016.08.002. Epub 2016 Aug 13.
9
Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?肠道微生物组与地高辛失活:地高辛使用者的饮食计划?
World J Microbiol Biotechnol. 2014 Mar;30(3):791-9. doi: 10.1007/s11274-013-1507-x. Epub 2013 Oct 9.
10
Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.强力霉素在疟疾化学预防和治疗中的应用:美国疾病预防控制中心疟疾化学预防专家会议报告。
Am J Trop Med Hyg. 2011 Apr;84(4):517-31. doi: 10.4269/ajtmh.2011.10-0285.